A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment. Using this strategy, researchers demonstrated the effectiveness of a new combination therapy that enhances tumor response while reducing cardiac inflammation. This new paradigm, presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting, offers a more comprehensive assessment of therapeutic impact, supporting more personalized clinical decision‑making.

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a patient's long-term survival. Outcomes data revealed that patients with even just one bone metastasis experience faster disease progression and worse overall survival. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

Shannon Youngblood, EdD, MSRS, CNMT, RT(CT)(ARRT), has been elected president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). The new slate of officers was introduced during the SNMMI's 2026 Annual Meeting, held May 30 - June 2 in Los Angeles.

Sara L. Johnson, EdD, MAEd, BS, CNMT, NMTCB(RS), RT(N)(CT)(ARRT), FSNMMI-TS, has been named president-elect of the SNMMI Technologist Section (SNMMI-TS). Johnson is a PET/CT technologist at Florida Cancer Specialists in Brandon, Florida, and a didactic instructor at Gurnick Academy of Medical Arts. SNMMI introduced its 2026-27 officers at its 2026 Annual Meeting, held May 30 - June 2 in Los Angeles.

A specific pattern of brain metabolism visualized with PET imaging can predict which patients are most likely to benefit from Alzheimer's disease therapy. In a retrospective study of patients who received Alzheimer's treatments, those with the identified pattern experienced stabilized cognitive performance, while patients with other patterns had significant cognitive decline. This study was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, where it received top recognition as the Abstract of the Year.

Richard E. Carson, PhD, has been named the 2026 recipient of the prestigious Paul C. Aebersold Award. Carson is professor of Biomedical Engineering and of Radiology and Biomedical Imaging at Yale University in New Haven, Connecticut, as well as emeritus director of the Yale PET Center. The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2026 Annual Meeting.

Irène Buvat, PhD, a leading expert in molecular imaging quantification, is the recipient of SNMMI's George Charles de Hevesy Nuclear Pioneer Award, presented at the society's 2026 Annual Meeting, May 30 through June 2 in Los Angeles. Buvat's work has fundamentally changed how the field measures, models, and interprets molecular imaging data, laying the scientific groundwork for more accurate diagnosis and treatment of cancer.